UPEXI, INC. current report, 23 June 2021

Full document

Filing Overview

Grove, Inc. filed a Form 8-K dated June 23, 2021, with subsequent events through June 28, 2021. The filing concerns the company’s initial public offering, Nasdaq Capital Market listing, issuance of a representative’s warrant, and a management appointment. The request metadata identifies UPEXI, Inc., while the filing names Grove, Inc.; this discrepancy should be verified.

Offering and Key Financial Metrics

  • The company entered into a firm-commitment underwriting agreement for an IPO of common stock.
  • The base offering comprised 2,200,000 shares at a public offering price of $5.00 per share.
  • The underwriters fully exercised a 45-day over-allotment option for 330,000 additional shares, resulting in 2,530,000 shares sold.
  • Total gross proceeds were approximately $12.65 million.
  • Net proceeds were approximately $11.3865 million after underwriting commissions, discounts, and offering expenses.
  • The filing does not provide operating revenue, profit, cash flow, margin, debt, or post-offering liquidity metrics.

Material Changes and Securities Issuances

  • The offering closed on June 28, 2021, following the June 23 underwriting agreement.
  • The company issued the underwriters’ representative a warrant to purchase up to 50,600 shares, representing 2% of the shares sold.
  • The warrant has an initial exercise price of $6.25 per share, equal to 125% of the offering price, and is exercisable from December 21, 2021 through June 24, 2026.
  • On June 25, 2021, Andrew J. Norstrud was appointed Secretary while continuing to serve as Chief Financial Officer.

Outlook, Risks, and Unusual Items

  • The filing does not provide financial guidance, forecasts, or management commentary regarding future operating performance.
  • The underwriting agreement contains customary representations, warranties, covenants, and indemnification obligations, including indemnification relating to Securities Act liabilities.
  • The representative’s warrant and the potential issuance of additional shares may result in future dilution if exercised.
  • The filing does not describe specific use-of-proceeds plans, contingencies, or material litigation.

Investor Verification Priorities

  1. Verify the registrant’s identity and relationship between Grove, Inc. and UPEXI, Inc., given the discrepancy between the request metadata and filing text.
  2. Review the underwriting agreement for final offering expenses, indemnification obligations, and other transaction terms.
  3. Confirm receipt and intended use of the approximately $11.3865 million in net proceeds.
  4. Assess potential dilution from the 50,600-share representative’s warrant and any other outstanding securities.
  5. Review subsequent filings for operating results, liquidity, debt, and the company’s post-IPO financial condition.